Literature DB >> 33348237

Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment.

Ying Sun1, Yunlong Lu1, Mianli Bian1, Zhibin Yang1, Xiaoyan Ma1, Wukun Liu2.   

Abstract

The effective application of cisplatin in the clinic as an antitumor treatment has stimulated widespread interest in inorganic metal drugs. In particular, complexes containing the transition metals platinum and gold have attracted considerable attention due to their antitumor effects. The Pt(II) and Au(III) Schiff-base complexes are potential antitumor agents because of their remarkable biological activities and good stability, lipophilicity, and electroluminescent properties. These complexes act via various antitumor mechanisms that are unlike those of the classic platinum drugs, providing a feasible solution for improving the serious side effects caused by metal chemotherapy. In this review, promising antitumor agents based on Pt(II) and Au(III) complexes containing Schiff-base ligands, and their biological targets, including G-quadruplex DNA and thioredoxin reductase, are comprehensively summarized.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antitumor; Au(III) complexes; Biological targets; Pt(II) complexes; Schiff-base ligands

Mesh:

Substances:

Year:  2020        PMID: 33348237     DOI: 10.1016/j.ejmech.2020.113098

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

1.  Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application.

Authors:  Ruixi Xu; Yuting Wu; Zhe Liu; Jinfeng Liu; Xicheng Liu
Journal:  Front Chem       Date:  2022-05-10       Impact factor: 5.545

2.  Antimicrobial and Antioxidant Activities of N-2-Hydroxypropyltrimethyl Ammonium Chitosan Derivatives Bearing Amino Acid Schiff Bases.

Authors:  Jingmin Cui; Xia Ji; Yingqi Mi; Qin Miao; Fang Dong; Wenqiang Tan; Zhanyong Guo
Journal:  Mar Drugs       Date:  2022-01-19       Impact factor: 5.118

3.  Revisiting salicylidene-based anion receptors.

Authors:  Sandeep Kumar Dey; Sonam Kumari; Sonal Mandrekar; Shashank N Mhaldar; Sarvesh S Harmalkar; Christoph Janiak
Journal:  RSC Adv       Date:  2021-11-17       Impact factor: 4.036

4.  Design, synthesis, molecular modeling, and bioactivity evaluation of 1,10-phenanthroline and prodigiosin (Ps) derivatives and their Copper(I) complexes against mTOR and HDAC enzymes as highly potent and effective new anticancer therapeutic drugs.

Authors:  M Mustafa Cetin; Wenjing Peng; Daniel Unruh; Michael F Mayer; Yehia Mechref; Kemal Yelekci
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.